+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunoprotein Diagnostic Testing Market by Assay Type, Technology, End User, Application, Sample Type - Global Forecast to 2030- Product Image
Immunoprotein Diagnostic Testing Market by Assay Type, Technology, End User, Application, Sample Type - Global Forecast to 2030- Product Image
Sale

Immunoprotein Diagnostic Testing Market by Assay Type, Technology, End User, Application, Sample Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888817
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Immunoprotein Diagnostic Testing Market grew from USD 9.41 billion in 2024 to USD 10.07 billion in 2025. It is expected to continue growing at a CAGR of 6.94%, reaching USD 14.08 billion by 2030.

Unveiling the Dynamics of Immunoprotein Diagnostic Testing

Immunoprotein diagnostic testing stands at the forefront of modern healthcare, providing critical insights into disease detection, patient monitoring, and therapeutic guidance. As the global healthcare ecosystem becomes increasingly complex, immunoprotein assays offer unparalleled specificity and versatility by targeting antibodies, antigens, and autoantibodies across a spectrum of clinical applications. This executive summary distills the essential trends and drivers shaping this dynamic market, examining technological breakthroughs, regulatory influences, and evolving clinical needs.

Decision-makers in pharmaceutical firms, diagnostic laboratories, and research institutes require a concise yet thorough understanding of how immunoprotein diagnostic platforms are reshaping disease management protocols. By exploring the interplay between technological innovation and market dynamics, this summary equips stakeholders with the strategic context necessary to capitalize on emerging opportunities. Informed by rigorous research and expert validation, the analysis that follows illuminates the critical factors influencing market growth, competitive positioning, and value-creation pathways.

Emerging Paradigms Reshaping Immunoprotein Diagnostics

Rapid advancements in assay automation and digital integration are redefining the landscape of immunoprotein diagnostics. High-throughput platforms equipped with real-time data analytics are accelerating turnaround times and enabling more precise quantification of immunoproteins, while cloud-enabled workflows are fostering remote collaboration and streamlined data sharing.

Concurrently, the rise of point-of-care immunoassays is democratizing access to rapid diagnostics outside traditional laboratory settings, allowing clinicians to deliver timely interventions in outpatient clinics and remote locations. Regulatory bodies are responding with adaptive frameworks that facilitate expedited approvals for novel platforms, especially those leveraging multiplexed detection and microfluidic technologies. Personalized medicine initiatives are further driving demand for immunoprotein tests that stratify patient populations based on biomarker profiles, thereby optimizing therapeutic regimens and improving clinical outcomes.

Taken together, these developments underscore a pivotal shift from one-size-fits-all diagnostics toward precision-driven, patient-centric strategies, heralding a new era in disease surveillance and management.

Navigating the 2025 Tariff Landscape in Immunoprotein Diagnostics

In 2025, new tariff measures imposed by the United States will introduce significant cost considerations for laboratory reagents, assay kits, and diagnostic instrumentation. Components imported from key manufacturing hubs are subject to increased duties, placing pressure on supply chain economics and compelling organizations to reevaluate vendor agreements. The immediate impact involves elevated procurement costs, which may be passed on to healthcare providers or absorbed through margin adjustments.

These tariffs amplify the strategic importance of vertical integration and regional manufacturing. Diagnostic firms are exploring nearshoring initiatives to secure domestic supply of critical assay components and mitigate exposure to tariff volatility. Simultaneously, collaborative alliances between instrument OEMs and reagent producers are emerging to synchronize production schedules and optimize logistical efficiencies.

Despite potential headwinds, industry leaders anticipate that the elevated cost structure will incentivize process innovations, cost-reduction efforts, and alternative sourcing strategies. Firms that proactively adapt to the 2025 tariff regime will not only preserve profitability but may also unlock new efficiencies across their immunoprotein diagnostic portfolios.

Dissecting the Market Through Core Diagnostic Segments

A granular assessment of the immunoprotein testing market reveals multiple axes of differentiation. When viewed through the lens of assay type, the category encompasses antibody tests differentiated by immunoglobulin class-IgA, IgE, IgG, IgM and total antibody-as well as antigen tests and autoantibody evaluations. Technology segmentation highlights methodologies such as CLIA, ELISA, fluorescence polarization immunoassay, lateral flow immunoassay and Western blot, each offering distinct trade-offs in sensitivity, throughput and workflow integration.

End users range from outpatient clinics and hospital laboratories to dedicated diagnostic centers and research institutes, reflecting the modality’s broad clinical penetration. Application-driven analysis spans autoimmune disorders-namely multiple sclerosis, rheumatoid arthritis, Sjögren syndrome and type 1 diabetes-cardiovascular conditions, infectious diseases including COVID-19, hepatitis, HIV and influenza, and oncology. Sample type also informs market dynamics, with plasma, serum, urine and whole blood as the primary specimen matrices underpinning assay development and performance characteristics.

By synthesizing these dimensions of segmentation, stakeholders gain a holistic perspective on where to focus R&D investments, refine market entry approaches and address unmet clinical needs with tailored immunoprotein solutions.

Regional Dynamics Driving Global Diagnostic Trends

Geographic analysis underscores distinct regional trajectories in immunoprotein diagnostic adoption. In the Americas, robust healthcare infrastructure and favorable reimbursement policies drive rapid uptake of advanced immunoassay platforms in North America, while Latin American markets are witnessing incremental growth fueled by expanding public health initiatives and private-sector partnerships. The Europe, Middle East & Africa region presents a heterogeneous landscape: Western European markets benefit from stringent regulatory harmonization and high per-capita testing rates, whereas emerging economies in the Middle East and Africa are prioritizing diagnostic capacity building to address infectious disease burdens.

Meanwhile, the Asia-Pacific region represents a critical growth frontier, propelled by increasing healthcare expenditure, rising incidence of chronic and infectious diseases, and government-led programs to enhance laboratory networks. Markets such as China, India and Southeast Asia are advancing local production capabilities and fostering collaborations between global diagnostic leaders and regional stakeholders. These regional dynamics underscore the importance of tailored market strategies that account for regulatory frameworks, healthcare delivery models and patient-centric considerations across diverse geographies.

Strategic Maneuvers by Leading Diagnostic Innovators

Leading industry players have adopted distinct strategic approaches to fortify their immunoprotein diagnostic portfolios. Roche Diagnostics continues to leverage its broad reagent and instrumentation ecosystem, integrating next-generation automation with digital service offerings. Abbott Laboratories has focused on expanding its point-of-care footprint through compact lateral flow immunoassay devices, enhancing accessibility in decentralized settings.

Thermo Fisher Scientific maintains momentum by combining assay innovation with end-to-end laboratory automation solutions, while Danaher Corporation’s consolidated diagnostics segment benefits from cross-brand synergies in reagent manufacturing and software platforms. Siemens Healthineers emphasizes digital pathology convergence and AI-driven analytics to augment immunoprotein testing accuracy. Emerging competitors such as Quidel and Bio-Rad Laboratories are carving niches through specialized assays and high-sensitivity platforms that address targeted clinical applications.

Collectively, these strategic maneuvers illustrate the competitive intensity and collaborative potential that define the immunoprotein diagnostics market, providing benchmarks for innovation, partnerships and ecosystem development.

Actionable Strategies for Sustained Market Leadership

Industry leaders aiming to secure and expand their market positions should prioritize investment in multiplexed immunoassay platforms that deliver simultaneous detection of multiple biomarkers, thereby enhancing clinical utility and operational efficiency. Collaborations with contract research organizations and academic institutions can accelerate the translation of novel autoantibody assays into clinical practice, fueling differentiation in autoimmune and oncology diagnostics.

Expanding manufacturing footprints through strategic partnerships or joint ventures in emerging markets will mitigate tariff-related supply risks while aligning production closer to growth regions. Companies should also integrate digital health solutions-such as cloud-based data management and AI-driven interpretation-to augment service offerings and create value-added revenue streams.

A proactive approach to regulatory engagement, including participation in collaborative review programs and early dialogue with approval agencies, will streamline time-to-market for next-generation assays. Finally, embedding sustainability principles into reagent development and packaging will resonate with increasingly environment-conscious stakeholders, fortifying brand reputation and ensuring long-term operational resilience.

Rigorous Framework Underpinning Market Intelligence

This research undertook a multi-phase methodology to ensure robustness and credibility. The foundation was built on extensive secondary research, including peer-reviewed literature, regulatory filings and industry white papers, to map existing immunoprotein assay technologies and market dynamics. Primary research involved in-depth interviews with key opinion leaders, diagnostics executives and clinical laboratory directors to validate assumptions and uncover emerging trends.

Quantitative data was triangulated through cross-referencing financial reports, public databases and proprietary intelligence sources, while qualitative insights were synthesized via expert panels to refine market segmentation and competitive assessments. Rigorous quality control measures, including consistency checks and iterative review cycles, were applied to guarantee analytical precision and actionable relevance.

Synthesis of Market Intelligence and Strategic Imperatives

The immunoprotein diagnostic testing arena is characterized by rapid technological evolution, changing regulatory landscapes and shifting cost structures. Through a detailed examination of assay modalities, technology platforms, end-user applications and regional dynamics, this summary highlights the critical drivers and barriers shaping market trajectories.

Organizations that embrace multiplexed assay development, digital integration and flexible manufacturing strategies will be best positioned to navigate tariff disruptions and competitive pressures. Meanwhile, a nuanced understanding of regional healthcare infrastructures and customer needs will inform successful go-to-market approaches. Ultimately, the synergistic application of these insights will enable stakeholders to deliver impactful diagnostic solutions, optimize clinical outcomes and achieve sustainable growth in an increasingly complex marketplace.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Assay Type
    • Antibody Test
      • Iga
      • Ige
      • Igg
      • Igm
      • Total Antibody
    • Antigen Test
    • Autoantibody Test
  • Technology
    • Clia
    • Elisa
    • Fluorescence Polarization Immunoassay
    • Lateral Flow Immunoassay
    • Western Blot
  • End User
    • Clinic
    • Diagnostic Laboratory
    • Hospital
    • Research Institute
  • Application
    • Autoimmune Disorders
      • Multiple Sclerosis
      • Rheumatoid Arthritis
      • Sjogren Syndrome
      • Type 1 Diabetes
    • Cardiovascular Diseases
    • Infectious Diseases
      • COVID-19
      • Hepatitis
      • Hiv
      • Influenza
    • Oncology
  • Sample Type
    • Plasma
    • Serum
    • Urine
    • Whole Blood
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc
  • Danaher Corporation
  • Ortho-Clinical Diagnostics, Inc.
  • bioMérieux SA
  • DiaSorin S.p.A
  • Bio-Rad Laboratories, Inc.
  • Fujirebio Inc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immunoprotein Diagnostic Testing Market, by Assay Type
8.1. Introduction
8.2. Antibody Test
8.2.1. Iga
8.2.2. Ige
8.2.3. Igg
8.2.4. Igm
8.2.5. Total Antibody
8.3. Antigen Test
8.4. Autoantibody Test
9. Immunoprotein Diagnostic Testing Market, by Technology
9.1. Introduction
9.2. Clia
9.3. Elisa
9.4. Fluorescence Polarization Immunoassay
9.5. Lateral Flow Immunoassay
9.6. Western Blot
10. Immunoprotein Diagnostic Testing Market, by End User
10.1. Introduction
10.2. Clinic
10.3. Diagnostic Laboratory
10.4. Hospital
10.5. Research Institute
11. Immunoprotein Diagnostic Testing Market, by Application
11.1. Introduction
11.2. Autoimmune Disorders
11.2.1. Multiple Sclerosis
11.2.2. Rheumatoid Arthritis
11.2.3. Sjogren Syndrome
11.2.4. Type 1 Diabetes
11.3. Cardiovascular Diseases
11.4. Infectious Diseases
11.4.1. COVID-19
11.4.2. Hepatitis
11.4.3. Hiv
11.4.4. Influenza
11.5. Oncology
12. Immunoprotein Diagnostic Testing Market, by Sample Type
12.1. Introduction
12.2. Plasma
12.3. Serum
12.4. Urine
12.5. Whole Blood
13. Americas Immunoprotein Diagnostic Testing Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Immunoprotein Diagnostic Testing Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Immunoprotein Diagnostic Testing Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Abbott Laboratories
16.3.3. Siemens Healthineers AG
16.3.4. Thermo Fisher Scientific Inc
16.3.5. Danaher Corporation
16.3.6. Ortho-Clinical Diagnostics, Inc.
16.3.7. bioMérieux SA
16.3.8. DiaSorin S.p.A
16.3.9. Bio-Rad Laboratories, Inc.
16.3.10. Fujirebio Inc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET MULTI-CURRENCY
FIGURE 2. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET MULTI-LANGUAGE
FIGURE 3. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IGA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IGG, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY IGM, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TOTAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOANTIBODY TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY CLIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY FLUORESCENCE POLARIZATION IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SJOGREN SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COVID-19, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 67. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 68. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 71. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 72. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 75. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 80. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 114. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 115. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 116. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 117. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 120. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 121. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 124. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 128. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 129. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 138. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 139. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 140. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 141. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 144. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 145. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 146. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 147. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 148. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 152. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 153. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 178. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 179. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 180. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 184. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 185. DENMARK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 189. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 192. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 194. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 195. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 196. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 200. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 201. QATAR IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 202. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 203. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 204. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 205. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 208. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 209. FINLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 224. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 225. NIGERIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 226. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 227. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 228. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 229. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 232. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 233. EGYPT IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 234. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 235. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 236. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 240. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 241. TURKEY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 250. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 251. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 252. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 253. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 255. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 256. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 257. NORWAY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 258. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 259. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 260. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 261. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 264. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 265. POLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 268. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 272. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 273. SWITZERLAND IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 280. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 282. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 283. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 284. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 285. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 286. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 289. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 290. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 291. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 292. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 293. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 294. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 296. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 297. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 298. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 299. JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 300. JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 301. JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 302. JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Immunoprotein Diagnostic Testing market report include:
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc
  • Danaher Corporation
  • Ortho-Clinical Diagnostics, Inc.
  • bioMérieux SA
  • DiaSorin S.p.A
  • Bio-Rad Laboratories, Inc.
  • Fujirebio Inc

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 10.07 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.08 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Immunoprotein Diagnostic Testing Market Size, Share & Trends Analysis Report By Test (Immunoglobulin Diagnostic Tests), By Technology, By Application, By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Immunoprotein Diagnostic Testing Market Size, Share & Trends Analysis Report By Test (Immunoglobulin Diagnostic Tests), By Technology, By Application, By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 180 Pages
  • Global
From
Immunoprotein Diagnostic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Immunoprotein Diagnostic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Immunoprotein Diagnostic Testing - Global Strategic Business Report - Product Image

Immunoprotein Diagnostic Testing - Global Strategic Business Report

  • Report
  • 171 Pages
  • Global
From
Immunoprotein Market by Product, Application, End User, Technology, Distribution Channel - Global Forecast to 2030 - Product Image

Immunoprotein Market by Product, Application, End User, Technology, Distribution Channel - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
2025 Global Immunoprotein Testing Market: Unmet Needs, Supplier Shares and Strategies, Segment Volume and Sales Forecasts for 13 Assays, Emerging Technologies and Trends, Growth Opportunities for Suppliers - Product Image

2025 Global Immunoprotein Testing Market: Unmet Needs, Supplier Shares and Strategies, Segment Volume and Sales Forecasts for 13 Assays, Emerging Technologies and Trends, Growth Opportunities for Suppliers

  • Report
  • 297 Pages
  • Global
From

About the Immunoprotein Testing Market

Immunoprotein testing is a type of diagnostic test used to detect the presence of specific proteins in the body. These proteins are produced by the immune system in response to a variety of conditions, including infections, autoimmune diseases, and cancer. Immunoprotein tests are used to diagnose and monitor a wide range of diseases, including HIV, hepatitis, and tuberculosis. They can also be used to detect the presence of antibodies, which can indicate a previous exposure to a particular virus or bacteria. Immunoprotein tests are typically performed in a laboratory setting, using a variety of techniques such as enzyme-linked immunosorbent assays (ELISA) and immunofluorescence assays (IFA). These tests are often used in combination with other diagnostic tests, such as blood tests, to provide a more comprehensive picture of a patient's health. The immunoprotein testing market is a rapidly growing segment of the diagnostics industry. It is driven by the increasing prevalence of infectious diseases, the growing demand for personalized medicine, and the development of new technologies. Some of the major players in the immunoprotein testing market include Abbott Laboratories, Becton Dickinson, Bio-Rad Laboratories, Cepheid, DiaSorin, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.